Published 2018 | Version v1
Publication Metadata-only

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations

Helgadottir, Hildur
Ghiorzo, Paola
van Doorn, Remco
Puig, Susana
Levin, Max
Kefford, Richard
Lauss, Martin
Queirolo, Paola
Pastorino, Lorenza
Kapiteijn, Ellen
Potrony, Miriam
Carrera, Cristina
Olsson, Håkan
Höiom, Veronica
Jönsson, Göran
Others:
Helgadottir, Hildur
Ghiorzo, Paola
van Doorn, Remco
Puig, Susana
Levin, Max
Kefford, Richard
Lauss, Martin
Queirolo, Paola
Pastorino, Lorenza
Kapiteijn, Ellen
Potrony, Miriam
Carrera, Cristina
Olsson, Håkan
Höiom, Veronica
Jönsson, Göran

Description

Inherited CDKN2A mutation is a strong risk factor for cutaneous melanoma. Moreover, carriers have been found to have poor melanoma-specific survival. In this study, responses to novel immunotherapy agents in CDKN2A mutation carriers with metastatic melanoma were evaluated.

Additional details

Identifiers Origin repository
Created:
April 14, 2023
Modified:
November 29, 2023